摘要
目的:探讨肾透明细胞癌中Ki-67指数、EGFR表达及DNA倍体的临床意义。方法:经病理确诊的肾透明细胞癌66例患者的手术标本,用免疫组化染色法检测Ki-67指数及EGFR表达,流式细胞术检测DNA倍体,并分析其与临床病理特征之间的关系。结果:肾透明细胞癌Ki-67阳性细胞占59.4%(38/64),Ki-67指数与肿瘤分级(P<0.05)、DNA倍体异常(P<0.05)显著相关,与EGFR表达无相关性。EGFR蛋白表达阳性率为86.2%(56/65),其胞浆表达与肿瘤分级呈正相关(P<0.05);其胞膜和膜浆混合表达没有发现相关性。检测45例DNA倍体,31例(68.9%)为异倍体。结论:透明细胞癌中Ki-67指数和EGFR与肿瘤分级密切相关,提示Ki-67和EGFR有可能成为临床判断预后的重要分子指标。DNA异倍体与Ki-67指数显著相关,提示DNA也可能提示肾透明细胞癌临床预后。联合检测上述3种指标,并与临床指标结合,将能更准确地判断预后并指导临床治疗。EGFR在肾透明细胞癌中的高表达,使其可能成为个体化治疗的靶向分子。
Objective：To appraise Ki-67 label index, epidermal growth factor receptor（EGFR） expression and DNA aneuploid, and their clinical significance in clear cell type renal cell carcinoma （RCC）. Methods： hnmnnohistochemistry （IHC） method was applied to examine Ki-67 positive cells and the expression of EGFR. Flow cytometty was used to evaluate the DNA aneuploid and diploid. Results：Thirty-eight （59.4%） patients with clear cell renal carcinoma had Ki-67 positive cells. Ki-67 label index were sig- nificantly higher in high grading（ P 〈 0. 05 ） and DNA anuploid tumors（ P 〈 0.05 ）. However, there was no significant relationship between the expression of Ki-67 label index and EGFR. As to EGFR, their expressions were positive in 56 （86. 2% ） cases. The cytoplasmic expression of EGFR was statistically related with histological grading, whereas overall （cytoplasmic and membranous） immuno- reactivity and intensity of membranous staining were not. In term of DNA evaluation, 31 （68.9%） were DNA anupoid. Conclusion： The closely positive correlations of Ki-67 labeling indices, EGFR expression and tumor grading might be served as an important factor for the clinical prognosis. In addition, DNA anuploid possibly help improve the correction of the prognosis in clear cell type RCC. Thus, combinational examination of above three targets, molecular marker rather than only the clinical data, possibly play a significant role of determining tumor biological behavior and instructing therapy. The high expression of EGFR showed that it might be the target molecular for individual therapy.
出处
《临床肿瘤学杂志》
CAS
2009年第6期505-509,共5页
Chinese Clinical Oncology
